The translocator protein (18 kDa): central nervous system disease and drug design.
about
Structure of the mitochondrial translocator protein in complex with a diagnostic ligandNickel-catalysed aromatic Finkelstein reaction of aryl and heteroaryl bromidesIn vivo imaging of microglial activation by positron emission tomography with [(11)C]PBR28 in the 5XFAD model of Alzheimer's diseaseTranslocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative DiseasesMolecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations.Increase in blood-brain barrier permeability, oxidative stress, and activated microglia in a rat model of blast-induced traumatic brain injury.Loss of functional GABA(A) receptors in the Alzheimer diseased brain.Solution structures of the prototypical 18 kDa translocator protein ligand, PK 11195, elucidated with 1H/13C NMR spectroscopy and quantum chemistry.Synthesis of [(125)I]iodoDPA-713: a new probe for imaging inflammation.The mitochondria permeability transition pore complex in the brain with interacting proteins - promising targets for protection in neurodegenerative diseases.Molecular tracers for the PET and SPECT imaging of disease.Imaging of microglia in patients with neurodegenerative disorders.The potential of carbon-11 and fluorine-18 chemistry: illustration through the development of positron emission tomography radioligands targeting the translocator protein 18 kDa.The translocator protein as a drug target in Alzheimer's disease.The translocator protein as a potential molecular target for improved treatment efficacy in photodynamic therapy.Translocator protein (18 kDa): an update on its function in steroidogenesis.Synthesis, characterization, and in vitro evaluation of new coordination complexes of platinum(II) and rhenium(I) with a ligand targeting the translocator protein (TSPO).A model radiopharmaceutical agent targeted to translocator protein 18 kDa (TSPO).Synthesis and cellular uptake of boron-rich pyrazolopyrimidines: exploitation of the translocator protein for the efficient delivery of boron into human glioma cells.Three-dimensional structure of TspO by electron cryomicroscopy of helical crystals.Synthesis, Characterization, and in Vitro Evaluation of a New TSPO-Selective Bifunctional Chelate Ligand.Synthesis, Characterization, and Cytotoxicity of the First Oxaliplatin Pt(IV) Derivative Having a TSPO Ligand in the Axial Position.Effects of translocator protein (18 kDa) ligands on microglial activation and neuronal death in the quinolinic-acid-injected rat striatum.Conformational Flexibility in the Transmembrane Protein TSPONickel-mediated radioiodination of aryl and heteroaryl bromides: rapid synthesis of tracers for SPECT imaging.A novel 18F-labelled high affinity agent for PET imaging of the translocator protein.Bridging Pharmaceutical Chemistry with Drug and Nanoparticle Targeting to Investigate the Role of the 18-kDa Translocator Protein TSPO.Imaging of Glial Activation in Alzheimer's DiseaseLate stage iodination of biologically active agents using a one-pot process from aryl aminesStructure–activity relationships of novel iodinated quinoline-2-carboxamides for targeting the translocator protein
P2860
Q27689579-A579533B-C95D-406A-ADE4-67D905B92738Q28262026-A7CC8B32-EEFF-43B7-B713-507EE584EE0BQ28274003-6F3E45D7-CDA4-4577-9B41-11CE1E4EF271Q33624586-EF31156E-5FD4-4575-98BF-1AFD59CC47A0Q33624653-E52CCC1C-86A3-46DC-BB71-5C8D72AA7C6EQ34249725-B15C65D1-6161-4ED9-A379-FEC58651051FQ36056348-F4A7F0F1-C2C8-42DD-A510-EA252F65A5E0Q36109447-E8C30D30-FA7D-44BC-931A-DBA9FC57F284Q37392949-DC15F1B6-26F6-4383-8662-7B698B823EE8Q37724783-F4569A94-9F31-4CF7-B6A8-BDB77C2E5AACQ37785499-F3FEDA61-DCE7-4F76-A3B0-41060F2FEECFQ38015834-12C40EEA-2673-401F-AFB4-090765FCA092Q38166963-5DA1C6F4-BA44-43C8-8843-8871C6E99169Q38195637-299F2463-11FE-4B34-9BE3-F1ECBAF6FD6CQ38221277-5DEEE0BF-5F32-4B48-A152-602C4EAA3F66Q38698954-4E19F88C-A8DB-433C-868D-45245ADC29C0Q38970921-E59EE347-06D8-4F4C-858E-F83D90000E85Q39141541-82BAA2AE-A788-4477-8961-F457B913039AQ39459275-69874B11-B7F8-45FE-A734-1539E8301EBDQ39864742-4AEE24E1-A401-4165-B924-8B2BCD158702Q40809454-9D4B3204-2D27-4C50-86BA-9657A60964DBQ41865609-25F42DB8-9234-4B33-BDC1-53895A82E10EQ41964688-8A95BEFF-3BAD-4B60-A925-594208246517Q42641190-FAF2C2D0-A6A7-47AC-B3C7-A6966A37B154Q43485330-84E1E70A-47A4-4850-9AE3-EE7BADA5C251Q45103335-D97130AA-A49D-4E85-987D-1F7BAAAC7FFAQ47994873-46B19B14-F8FC-4E2A-A5CE-8E8E03A3F0E4Q58797155-309984CE-1168-4B38-A68C-BB0D38A1A2C7Q58856756-404D3C19-D296-4DF2-8973-73C0FFD966B3Q58856822-8B797F76-042D-48F2-AB3F-02CC53FBFF84
P2860
The translocator protein (18 kDa): central nervous system disease and drug design.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The translocator protein (18 kDa): central nervous system disease and drug design.
@en
The translocator protein
@nl
type
label
The translocator protein (18 kDa): central nervous system disease and drug design.
@en
The translocator protein
@nl
prefLabel
The translocator protein (18 kDa): central nervous system disease and drug design.
@en
The translocator protein
@nl
P356
P1476
The translocator protein (18 kDa): central nervous system disease and drug design.
@en
P2093
Alana M Scarf
Michael Kassiou
P304
P356
10.1021/JM8011678
P407
P577
2009-02-01T00:00:00Z